STAT+: White House official dings Bristol Myers Squibb for fighting off generic competition
A White House Domestic Policy Council deputy criticized Bristol Myers Squibb's efforts to fight off generic competition for a popular blood thinner.
WASHINGTON — A top White House official on Tuesday delivered a pointed attack at a drugmaker fighting the administration’s Medicare negotiation plan in court.
Christen Linke Young, White House Domestic Policy Council’s deputy assistant to the president for health and veterans affairs, took on Bristol Myers Squibb, which makes the blockbuster blood thinner Eliquis. Eliquis is one of 10 high-cost drugs the federal program has targeted first for negotiated prices.
“The manufacturer of that drug spent most of 2020 in court trying to fend off generic competition,” she said at a Tuesday STAT event here. Generic drugmakers sued BMS in 2019 to challenge the drug’s patents.
What's Your Reaction?
